Intrexon, Oragenics ally in the development of antibiotics
Executive Summary
Probiotics developer Oragenics Inc. will use synthetic biology firm Intrexon Corp.’s transgene and cell engineering platforms--such as UltraVector--in the development of lantibiotics as APIs for treating infectious diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Transgenics
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice